Salvage therapy with combined cyclophosphamide (C), fludarabine (F), alemtuzumab (A), and rituximab (R) (CFAR) for heavily pre-treated patients with CLL.

被引：0
|
作者：
Wierda, WG [1 ]
OBrien, S [1 ]
Ferrajoli, A [1 ]
Faderl, S [1 ]
Koller, C [1 ]
Giles, F [1 ]
Cortes, J [1 ]
Thomas, D [1 ]
Ravandi, F [1 ]
Garcia-Manero, G [1 ]
Andreeff, M [1 ]
Lerner, S [1 ]
Kantarjian, H [1 ]
Keating, M [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
719
引用
收藏
页码：213A / 213A
页数：1
相关论文
共 48 条
  • [41] First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group
    Hallek, Michael
    Fingerle-Rowson, Guenter
    Fink, Anna-Maria
    Busch, Raymonde
    Mayer, Jiri
    Hensel, Manfred
    Hopfinger, Georg
    Hess, Georg
    von Gruenhagen, Ulrich
    Bergmann, Manuela A.
    Catalano, John
    Zinzano, Pier Luigi
    Cappio, Federico Caligaris
    Seymour, John F.
    Berrebi, Alain
    Jaeger, Ulrich
    Cazin, Bruno
    Trneny, Marek
    Westermann, Anne
    Wendtner, Clemens-Martin
    Eichhorst, Barbara F.
    Staib, Peter
    Boettcher, Sebastian
    Ritgen, Matthias
    Mendila, Myriam
    Kneba, Michael
    Doehner, Hartmut
    Stilgenbauer, Stephan
    Fischer, Kirsten
    BLOOD, 2009, 114 (22) : 223 - 224
  • [42] CAPECITABINE (XEL) AND MITOMYCIN-C (MMC) AS SALVAGE THERAPY FOR PATIENTS (PTS) WITH ADVANCED BREAST CANCER (ABC) PRE-TREATED WITH ANTHRACYCLINES AND TAXANES. A PHASE II STUDY
    Massacesi, Cristian
    La Cesa, Annalisa
    Pilone, Alberta
    Santini, Daniele
    Zepponi, Laura
    Tonini, Giuseppe
    Bonsignori, Maurizio
    ANNALS OF ONCOLOGY, 2004, 15 : 19 - 19
  • [43] Quadruple Nucleos(t)ide Reverse Transcriptase Inhibitors-Only Regimen of Tenofovir Plus Zidovudine/Lamivudine/Abacavir in Heavily Pre-Treated HIV-1 Infected Patients: Salvage Therapy or Backbone Only?
    Stephan, Christoph
    Dauer, Brenda
    Khaykin, Pavel
    Stuermer, Martin
    Gute, Peter
    Klauke, Stephan
    Staszewski, Schlomo
    CURRENT HIV RESEARCH, 2009, 7 (03) : 320 - 326
  • [44] Safety and Efficacy of Abbreviated Induction with Oral Fludarabine (F) and Cyclophosphamide (C) Combined with Dose-Dense IV Rituximab (R) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) Aged > 65 years : Results of a Multicenter Trial (LLC 2007 SA) On Behalf of the French Goelams/Fcgcll-WM Intergroup
    Dartigeas, Caroline
    Van Den Neste, Eric
    Berthou, Christian
    Maisonneuve, Herve
    Lepretre, Stephane
    Dilhuydy, Marie-Sarah
    Bene, Marie-Christine
    Nguyen-Khac, Florence
    Letestu, Remi
    Cymbalista, Florence
    De Guibert, Sophie
    Aurran, Therese
    Laribi, Kamel
    Vilque, Jean Pierre
    Tournilhac, Olivier
    Delmer, Alain
    Feugier, Pierre
    Cazin, Bruno
    Michallet, Anne-Sophie
    Levy, Vincent
    Troussard, Xavier
    Delepine, Roselyne
    Giraudeau, Bruno
    Colombat, Philippe
    Leblond, Veronique
    BLOOD, 2012, 120 (21)
  • [45] Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
    Forstpointner, Roswitha
    Unterhalt, Michael
    Dreyling, Martin
    Boeck, Hans-Peter
    Repp, Roland
    Wandt, Hannes
    Pott, Christiane
    Seymour, John F.
    Metzner, Bernd
    Haenel, Annette
    Lehmann, Tanja
    Hartmann, Frank
    Einsele, Hermann
    Hiddemann, Wolfgang
    BLOOD, 2006, 108 (13) : 4003 - 4008
  • [46] CLL2007FMP, a Phase III Randomized Multicentric Trial of the French Cooperative Group On CLL and WM (FCGCLL/MW) and the "Groupe Ouest-Est D'etudes Des Leucemies Aigues Et Autres Maladies Du Sang" (GOELAMS): Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Yields a Significantly Better Response Than Fludarabine (F), Cyclophosphamide (C) and MabCampath (Cam) (FCCam) In Previously Untreated B-Chronic Lymphocytic Leukemia Patients as Evaluated by a Sensitive 6 Color Flow Cytometry MRD
    Remi, Letestu
    Lepretre, Stephane
    Christine, Arnoulet
    Lucille, Baseggio
    Lydia, Campos
    Bernard, Chatelain
    Marie-Christine, Jacob
    Eric, Legac
    Magali, Legarff-Tavernier
    Michel, Ticchioni
    Nelly, Robillard
    Roselyne, Delepine
    Vincent, Levy
    Sandrine, Katsahian
    Hugo, Varet
    Veronique, Leblond
    Florence, Cymbalista
    Pierre, Feugier
    BLOOD, 2010, 116 (21) : 307 - 308
  • [47] Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine (FIT Cyclophosphamide (C) and MabCampath (Cam) (FCCam) in Previously Untreated Patients (pts) with Advanced B-Chronic Lymphocytic Leukemia (B-CLL) : Experience On Safety and Efficacy within a Randomised Multicenter Phase III Trial of the french Cooperative Group On CIA, and WM (FCGCLL/MW) and the "Groupe Ouest-Est d'Etudes Des Leucemies Aigues Et Autres Maladies Du sang" (GOELAMS): CLL2007FMP (for fit medically patients)
    Lepretre, Stephane
    Aurran, Therese
    Mahe, Beatrice
    Cazin, Bruno
    Tournihlac, Olivier
    Maisonneuve, Herve
    Casasnovas, Olivier
    Delmer, Alain
    Leblond, Veronique
    Royer, Bruno
    Corront, Brigitte
    Chevret, Sylvie
    Delepine, Roselyne
    Vaudaux, Sandrine
    Van Den Neste, Eric
    Bene, Marie-Christine
    Cymbalista, Florence
    Feugier, Pierre
    BLOOD, 2009, 114 (22) : 225 - 225
  • [48] HEALTH-RELATED QUALITY OF LIFE OF NARATUXIMAB EMTASINE plus RITUXIMAB (N plus R) IN SECOND LINE AND HEAVILY PRE-TREATED PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): AN ANALYSIS OF THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY LYMPHOMA (FACT-LYM) MEASURE AND MAPPED EQ-5D VALUES FROM A PHASE II TRIAL
    Orfanos, P.
    Peipert, J.
    Cella, D.
    Rechavi-Robinson, D.
    Gandola, A.
    Micallef, S.
    Brachet, S.
    Dymkowska, M.
    VALUE IN HEALTH, 2022, 25 (01) : S245 - S245
12345